Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
RELIEF THERAPEUTICS Holding ( (CH:RLF) ) has shared an announcement.
Relief Therapeutics and NeuroX have signed a definitive agreement to merge, creating a publicly listed AI-driven health tech company named MindMaze Therapeutics Holding SA. This merger positions the company as a leader in neurotherapeutic solutions, leveraging a robust commercialization network and a proprietary neuro-data engine for scalable precision medicine. The transaction, expected to close in December 2025, involves a significant equity exchange and aims to expand the company’s market presence and investor appeal, with plans to enhance visibility in the U.S. market.
The most recent analyst rating on (CH:RLF) stock is a Hold with a CHF3.00 price target. To see the full list of analyst forecasts on RELIEF THERAPEUTICS Holding stock, see the CH:RLF Stock Forecast page.
More about RELIEF THERAPEUTICS Holding
RELIEF THERAPEUTICS Holding SA is a biopharmaceutical company focused on providing innovative treatment options for specialty, unmet, and rare diseases. NeuroX Group SA, a Swiss-based company, specializes in digital neurotherapeutics and brain health technologies, having acquired strategic assets from MindMaze Group SA. The combined entity aims to lead in precision neurology and neurotherapeutic solutions.
Average Trading Volume: 24,027
Technical Sentiment Signal: Buy
Current Market Cap: CHF42.54M
For detailed information about RLF stock, go to TipRanks’ Stock Analysis page.